Mobile

A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-002272-24

A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to demonstrate non-inferiority in the percentage of subjects achieving a 12-week sustained virologic response (SVR12) of 12 weeks of treatment with ABT-493/ABT-530 to 12 weeks of treatment with Sofosbuvir and Daclatasvir and to assess safety of ABT-493/ABT-530 compared to Sofosbuvir and Daclatasvir in treatment-naïve adults with chronic HCV GT3 infection.

Critère d'inclusion

  • Chronic HCV Genotype 3 Infection

Liens